Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Patient-reported Tolerability and Loco-regional Control After Proton Therapy in Patients With Recurrent or Second Primary Head and Neck Cancer Eligible for Re-irradiation, a Multicentre Phase II Single Arm Trial

NCT07922967 is registered in ClinicalTrials.gov with Oslo University Hospital as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07922967 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Patient-reported Tolerability and Loco-regional Control After Proton Therapy in Patients With Recurrent or Second Primary Head and Neck Cancer Eligible for Re-irradiation, a Multicentre Phase II Single Arm Trial
Lead sponsor
Oslo University Hospital
Phase
Observational
Overall status
Recruiting
Start date
November 20, 2026
Completion date
June 20, 2045
Enrollment
60 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

head & neck cancer

Arms

As registered; 1 arm.

  • Recurrance/second primay disease of HNC Proton radiotherapy

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Tolerability -patient-reported dysphagia measured with EORTC QLQ-HN43 dysphagia scale From enrollment untill 6 Months post-treatment

    Change in patient-reported dysphagia measured with the EORTC QLQ-HN43 dysphagia scale group level mean score

Lead sponsor's other trials

Oslo University Hospital, most recent start first.

Similar trials

Same condition (Head and Neck Neoplasms) and phase, most recent start first.